Summary
Interleukin 6 (IL-6) is considered an important mediator of acute inflammatory responses. Moreover, IL-6 functions as a differentiation and growth factor of hematopoietic precursor cells, B cells, T cells, keratinocytes, neuronal cells, osteoclasts, and endothelial cells. IL-6 exhibits its action via a receptor complex consisting of a specific IL-6 receptor (IL-6R) and a signal transducing subunit (gp130). Soluble forms of both receptor components are generated by shedding and are found in patients with various diseases such as acquired immune deficiency syndrome, rheumatoid arthritis, and others. The function of the soluble (s)IL-6R in vivo is unknown. Since human (h)IL-6 acts on human and murine target cells, but routine IL-6 on murine cells only, we constructed transgenic mice expressing the hslL-6R. We report here that in the presence of hslL-6R, mice are hypersensitized towards hlL-6, mounting an acute phase protein gene induction at significantly lower IL-6 dosages compared to control animals. Furthermore, in hslL-6R transgenic mice, the detected acute phase response persists for a longer period of time. The IL-6/IL-6R complex prolongs markedly the IL-6 plasma half-life. Our results reinforce the role of the hslL-6R as an agonistic protein, help to understand the function of the hslL-6R in vivo, and highlight the significance of the receptor in the induction of the acute phase response.
I
L-6 is a multifunctional cytokine and plays a central role .as a differentiation and growth factor of hematopoietic precursor cells, B cells, T cells, keratinocytes, neuronal cells, osteoclasts, and endothelial cells (for reviews see references 1 and 2). Moreover, IL-6 modulates the transcription of several liver-specific genes during acute inflammatory states (3) . Altered IL-6 serum levels have been described in several hematological diseases such as plasmacytoma or Castleman's disease (4, 5) , mesangial glomemlonephritis (6), osteoporosis (7), cachexia (8) , rheumatoid arthritis (9), sepsis (10, 11) , and AIDS (12, 13) .
IL-6 exhibits its action on target cells by acting through a receptor complex consisting of a specific IL-6-binding protein (IL-6R) and a signal-transducing subunit (gp130). The IL-6/IL-6R complex induces the homodimerization of two gp130 molecules leading to a number of intracellular signaling events including activation of the transcription factor NF-IL-6, probably via the Ras-microtubulus-associated protein kinase cascade (14) , and activation of the Janus kinase/signal transducer and activator of transcription signaling pathway (15) (16) (17) .
Soluble forms of the IL-6R (sIL-6R) 1 and gpl30 (sgp130) are found in different body fluids and their concentrations may be elevated in patients with various inflammatory diseases such as AIDS and rheumatoid arthritis (13, (18) (19) (20) . They are generated by limited proteolysis and are released from the cell surface (21) (22) (23) . It has also been demonstrated that an IL-6R mRNA lacking the coding sequence for a transmembrane domain exists. This mRNA presumably derives from a differential splicing event and can lead to the synthesis of a sIL-6R protein (24) . The sIL-6R retains its ligand-binding capacity (25, 26) and associates with sgpl30 in the presence of IL-6 (23, 27) . In vitro experiments have demonstrated that in contrast to other soluble receptors, such as the receptors for IL-1 or TNF, which are known to 1Abbreviations used in this paper: hslL-6R, human soluble IL-6R; PEPCK, phosphoenolpyruvate carbox'ykinase; sIL-6R, soluble IL-6R.
inhibit the effects of their hgands (28) , slL-6R acts agonistically on cells that express gp130. Most recently, it was shown that heart muscle cells respond to IL-6 only in the presence of the slL-6R (29) . By this transsignaling pathway, slL-6R is able to activate target cells that express only gp130 molecules on their cell surface but lack membranebound IL-6R (30) .
Despite the in vitro studies cited above and the finding that soluble forms oflL-6R and gp130 are found in various diseases, the function of these soluble proteins in vivo is not understood. The species specificity of IL-6, which acts on human and murine cells, whereas routine IL-6 is only active on murine cells, was the basis to construct transgenic mice expressing the human slL-6R (hslL-6R) to study the role of the hslL-6R in vivo without the confounding effect of endogenous routine IL-6. Here we demonstrate that upon injection of human IL-6, transgenic mice expressing the hsIL-6R, are hypersensitized towards the IL-6-mediated acute phase response. Moreover, hslL-6R functions as a carrier protein for its ligand, thereby markedly prolonging the plasma half-life of IL-6.
Materials and Methods
Chemicals. Protein A-Sepharose CL-4B was obtained from Pharulacia (Freiburg, Germany). DMEM, MEM, and penicillin/ streptomycin were from Gibco (Eggenstein, Germany). FCS was from Seromed (Berlin, Germany). The preparation of the monospecific antiserum against IL-6R was described previously (26) . Recombinant human and recombinant murine IL-6 were prepared as described (3l, 32 (33) was cloned upstream from the hlL-6R cDNA. A BamHI site was inserted upstream the PEPCK promotor. A 1.2-kb DNA fragment corresponding to the 3' portion of the human 13-globin gene (34) followed by a poly-A site was inserted downstream from the hlL-6R cDNA between the SalI and the HindlII sites of the vector. The BamHI-BamHI fragment containing the entire construct (see Fig. 1 A) was gel purified and microinjected into the pronuclei of fertilized eggs of NMRI and B602F~ mice. Mice were screened for the presence ofhlL-6R by Southern blot of EcoRIHindlII-digested tail DNA.
Animal Treatment. Mice were maintained in a 12-h light--dark cycle under standard conditions and were provided with food and water ad libitum. Procedures involving animals and their care were conducted in conformi W with national and international laws and policies, rhlL-6 was injected intraperitoneally at doses indicated in the figures.
RNA Expression. Mice were killed by cervical dislocation and R.NA was isolated from different organs by the phenol/chloroform method (35) and subjected to Northern blot analysis. 5 Ixg of heat-denatured RNA per sample was fractionated on a 1% agarose gel with 7% formaldehyde. The separated RNA was transferred to GeneScreen Plus membranes (DuPont-New England Nuclear, Dreieich, Germany) according to the supplier's instructions. The filters were prehybridized at 68~ for 2 h in 10% dextran sulfate, 1 M NaC1, 1% SDS, and hybridized in the same solution with 32p-cDNA fragments labeled by random priming (36) . The following probes were used: a 0.9-kb Hinfl restriction fragment of human haptoglobin cDNA and a 1.2 PstI-XhoI restriction fragment ofhlL-6R cDNA.
Serum IL-6 Measurements and Cell Growth. Blood was drawn by cardiac punction under general anesthesia of the mice. A hlL-6 ELISA was performed according to the supplier's instructions. For the murine B9 proliferation assay, murine serum samples were serially diluted. The assay was performed as described (37) . One B9 unit corresponding to N1 pg hlL-6/ml led to half-maximal proliferation of B9 cells. Cells were grown in DMEM at 5% CO 2 in a water-saturated atmosphere. All cell culture media were supplemented with 10% FCS, 100 rag/liter streptomycin, and 60 rag/liter penicillin.
Serum IL-6/hslL-6R Complex and IL-6R Immunoprecipitation.
100 p~l ofmurine serum was preincubated with 100 Ixl of protein A-Sepharose (20 mg/ml) and 800 Ixl ofPBS/0.01% Tween for 2 h at 4~ After centrifugation, the supernatant was incubated with the monoclonal anti-IL-6R antibody MT18 for 4 h at 4~ Immune complexes were precipitated with 100 txl protein A-Sepharose for 2 h at 4~ separated by 12.5% SDS-PAGE, and subjected to Western blot analysis using a polyclonal specific antiserum against hlL-6R as previously described (26) .
Results

Generation of PEPCK/hslL-6R Transgenic Mice.
To drive expression of the hslL-6R in the liver oftransgenic mice, we used the promoter of the mouse PEPCK gene, which is neonatal and thereby permits one to evaluate the influence of gene products after birth (33) . The promoter has been shown to be specific for liver and kidney (38) . DNA ( Fig. 1 A) was microinjected into the pronuclei of fertilized eggs from NMRI mice. Four PEPCK/hslL-6R transgenic founders were obtained and verified by Southern blot analysis. Mice were interbred to obtain homozygous and heterozygous transgenic PEPCK/hslL-6R mice.
Characterization of PEPCK/hslL-6R Transgenic Mice. Tail
DNA was digested with EcoRI/HindlII and used for Southern blot analysis (Fig. 1 B) . In homozygous mice, the level of the transgene was twofold of that observed in heterozygous mice. As can be seen in Fig. 1 C, the hslL-6R-mRNA levels in homozygous mice were significantly higher than those observed in heterozygous mice. Accordingly, in immunoprecipitation experiments, the highest levels of hslL-6R were detected in homozygous mice (Fig. 1 D) . Transgenic mice expressed the shlL-6R in the low microgram range as determined by ELISA (data not shown). When Northern blot analysis was performed with RNA from different mouse tissues, hslL-6R-mRNA was detected in the liver and kidney, but not in heart, muscle, or brain (data not shown).
hlL-6 Does Not Influence the Expression ofhslL-6R. To ex-
clude the possibility that hlL-6 induces the murine PEPCK ,g) , prepared from the liver of 8-wk-old control mice and heterozygous and homozygous transgenic mice were subjected to Northern blot analysis and hybridized with a 32p-labeled 1.2-kb XlioI-Pstl-cDNA fragment. (D) hslL-6R was immunoprecipitated from mouse serum with the MT-18 antibody and subjected to Western blot analysis using a monospecific antiserum against hlL-6R.
promoter and drives the transcription of hslL-6R, R N A prepared from liver tissue from homozygous transgenic mice 4 h after receiving different dosages of human IL-6 was subjected to Northern blot analysis and was hybridized with a hslL-6R probe. Contemporaneously, blood was drawn from the mice, and the hslL-6R was immunoprecipitated with the monoclonal anti-IL-6R antibody MT18 and subjected to Western blot analysis. As can be seen from Fig. 2 , different dosages ofhlL-6 did not lead to changes ofhslL-6R m R N A or protein expression.
hslL-6R Transgenic Mice Are Hypersensitized towards the hlL-6-induced Acute Phase Protein Expression. One major activity of IL-6 is the induction of the hepatic acute phase response (39) . We therefore analyzed the induction of the acute phase protein gene expression by hlL-6 in the liver of hslL-6R transgenic mice. Various dosages of hlL-6 were administered to the mice intraperitoneally, and mice were killed after 4 h (Fig. 3) . In the top panel of Fig. 3 , the haptoglobin m R N A expression in control animals is demonstrated. The strongest haptoglobin expression was seen when 40 I~g hlL-6 was injected. In heterozygous hslL-6R transgenic mice (Fig. 3, middle) , the strongest haptoglobin expression was seen at a 10-fold lower dose (4 Ixg) compared to control animals. In homozygous hslL-6R mice (Fig. 3,  bottom) , a hlL-6 dose of as low as 0.4 pog induced a significant haptoglobin m R N A expression. These experiments clearly demonstrate that the hslL-6R renders transgenic mice more sensitive to hlL-6 in a dose-dependent fashion. In contrast, when control, heterozygous, and homozygous hslL-6R transgenic animals were injected with 8 p~g of murine IL-6 and analyzed 4 h after injection, an equal induction of the acute phase response was seen in all animals (data not shown).
In hslL-6R Transgenic Mice the IL-6-induced Acute Phase Protein Expression Is Markedly Prolonged. Time course ex-
periments were performed with 8 Ixg hlL-6 injected intraperitoneally (Fig. 4 A) . In control mice (Fig. 4 A, top) , the strongest haptoglobin m R N A expression was detected after 4 h, declined after 8 h, and was hardly detectable after 12 h. 
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In heterozygous h s l L -6 R transgenic mice (Fig. 4 A, middle), the strongest haptoglobin m R N A expression was o bserved as soon as 2 h after h u m a n IL-6 application and was detectable throughout the experiment. In homozygous h s l L -6 R mice (Fig. 4, bottom) , an increase of haptoglobin expression was seen 0.5 h after IL-6 application and, as in heterozygous mice, was more persistent. W h e n 8 p~g hlL-6 was given for longer periods of time (Fig. 4 B) to control animals (top), the strongest expression o f haptoglobin was seen after 8 h and declined thereafter.
In heterozygous mice (Fig. 4 B, middle) , the response was equally strong after 8 and 24 h; in homozygous h s l L -6 R mice (Fig. 4, bottom) , the expression o f haptoglobin peaked at 24 h and was still p r o n o u n c e d after 48 h w h e n compared to control animals ( Fig. 4 B, top) and heterozygous transgenic mice (Fig. 4 B, middle) .
slL-6R Functions as a Carrier Protein for IL-6 Prolonging the Serum Half-life oflL-6. T o investigate the fate o f h l L -6 in-
jected into I L -6 R transgenic mice, we determined IL-6 serum levels using the hlL-6 ELISA (Fig. 5 ) and a m u r i n e B9 assay. When dose--response experiments were performed, IL-6 levels were markedly elevated in heterozygous, and even higher in homozygous hslL-6R transgenic mice when compared to control animals (Fig. 5 A) . In the time course experiment, there were also markedly higher IL-6 levels in hslL-6R transgenic mice compared to control mice (Fig. 5  B) . IL-6 levels were undetectable 12 h after application in control animals, but were still significantly elevated 20 h after application in transgenic mice (Fig. 5 B) . Similar results were obtained when IL-6 levels were determined using the B9 assay (data not shown).
Discussion
To determine the role of the slL-6R in vivo, we made use of the species specificity ofhlL-6, which acts on human and murine IL-6R, in contrast to murine IL-6 which acts only on murine IL-6R. Transgenic mice expressing the hslL-6R were generated, and the function of the hslL-6R was studied in vivo without the confounding action of endogenous murine IL-6.
There are three major findings of this study. First, the slL-6R makes animals more sensitive to the cytokine IL-6. According to studies performed in cell culture, the slL-6R renders target cells more sensitive and enables cells to respond to IL-6 which by themselves do not bind the cytokine because of lack of surface expression of the membranebound IL-6R (18, 30) . The degree of sensitization we observed in the transgenic mice, however, exceeded by far the effect seen in cell culture: when hlL-6 was injected into hslL-6R transgenic animals and the IL-6-mediated acute phase proteine expression was measured, these mice were found to be 10--100-fold more sensitive towards hlL-6 as compared to control animals. In contrast, the injection of murine IL-6 did not result in an increased acute phase protein expression in hslL-6R transgenic mice when compared to control animals. This finding confirms the species specificity of murine IL-6, which has no effect on human target cells and argues against any interference of endogenous murine IL-6 with the hslL-6R. Since the acute phase response induced by murine IL-6 was equal in control, heterozygous, and homozygous hslL-6R transgenic animals, one can conclude that the binding of hlL-6 to membranebound and soluble murine IL-6 receptor does not contribute to the dose-dependent, IL-6-induced hypersensitization of hslL-6R transgenic mice demonstrated in our study. Second, time course experiments revealed that in hslL-6R transgenic animals, the IL-6-mediated acute phase response persisted much longer as compared with control animals. In homozygous hslL-6R transgenic mice, the acute phase response persisted as long as 48 h. Third, in hslL-6R transgenic animals, the IL-6 serum levels are markedly elevated and the plasma half-life of IL-6 is significantly prolonged. In a dose-dependent fashion, hslL-6R transgenic mice have two-to three-fold higher IL-6 serum levels as compared to control animals. Moreover, in time course experiments (Fig. 5 ) IL-6 levels are detectable for 20 h in hslL-6R transgenic animals, whereas in control mice, IL-6 levels could be measured for only 12 h. It is interesting that the IL-6 plasma levels are detectable longer in heterozygous hslL-6R transgenic mice than in homozygous mice (Fig. 5 B) . This effect becomes apparent after 4 h. One could argue that this represents a contradiction to the finding that in homozygous mice the acute phase response persists longer than in heterozygous mice (Fig. 4 B) . It is likely that there is an increased retention of the IL-6/ IL-6R complex in the circulation resulting in a prolongation of the half-life due to the increased size and stability of the complex. Moreover, it is well known that the IL-6/ IL-6R complex is internalized after activation of membrane-bound gpl30 (40, 41) . It is possible that the clearance of IL-6 and thus the IL-6 levels in vivo, are determined by an equilibrium between retention and internalization of the IL-6/IL-6R complex, which in the case of higher IL-6R levels, as measured in homozygous hslL-6R mice, is shifted towards internalization. This notion is supported by data from patients with sepsis, in whom highly increased IL-6 levels and significandy decreased slL-6R levels were measured when compared with control patients (42) .
Cytokine receptors are important in the regulation of cytokines and growth factors. There are multiple ways to regulate receptor function: (a) expression of receptors may be restricted to specific cell types; (b) the receptor number on the plasma membrane may vary because of receptor mRNA regulation or receptor internalization; (c) the receptor affinities may be modulated on some cells by additional membrane proteins that interact with the ligandbinding protein; or (d) the membrane-bound receptor may be transformed into a soluble form by limited proteolysis (28) . Not only cytokines have soluble counterparts, but also other transmembrane proteins, such as adhesion molecules (intercellular adhesion molecule 1) (43), the LPS-binding protein CD14 (44) , and the B and T cell membrane glycoproteins CD27 and CD40 (45) . Soluble receptors for most cytokines have been detected in many human body fluids, the majority inhibiting the function of their respective ligands. The slL-6R has been demonstrated to act agonisticaUy on cells bearing gp130 molecules on their surface if IL-6 is present. IL-6 serum levels detected in normal individuals are very low. It is noteworthy that at such concentrations there is litde or no responsiveness to this cytokine. In the presence of the slL-6R, however, such concentrations could stimulate target cells.
We have recently shown that melanoma cells transfected with the murine slL-6R, when injected into syngeneic mice, are much less effective in tumor induction or metastasis formation compared to untransfected melanoma cells (46, 47) . In this situation the sensitivity towards the endogenous murine IL-6 seems to be amplified by the presence of the slL-6R protein.
The biological importance of the shedding process as a major mechanism of generating soluble proteins is protean: (a) growth factors or cytokines are liberated such as TNF-a, TGF-a, and kit ligand; (b) soluble receptors are generated and act as competitors of the membrane-bound counterparts and thereby antagonize the cytokine response; and (c) for receptors of the IL-6 family (formally shown for the IL-6R and the receptor for the ciliary neurotrophic factor) and for the LPS receptor CD14, it has been demonstrated that the soluble proteins act as agonists, i.e., together with their ligands they are able to induce signaling on cells which by themselves are unresponsive to the ligand. This process has recently been termed transsignaling (28) . There is an increasing number of reports on cells being responsive to IL-6 only when IL-6R is present: bone resorption in vivo and in the osteoblast/osteoclast coculture (48) (49) (50) , CD34 § stem cell proliferation (51) , and the induction of alveolitis (52) are markedly enhanced in the presence of both IL-6 and IL-6R as compared to stimulation with IL-6 alone. In this context, generation of slL-6R not only has the effect of sensitization and prolongation, but also of a change of quality of the response. We were able to demonstrate that the phorbol ester PMA induces quantitative shedding of the slL-6R, indicating that protein kinase C is involved in this process (22, 53) . Most recently, we have shown that not only PMA, but also LPS markedly enhances shedding (54) , indicating that increased generation of the slL-6R might occur during bacterial infections. Based on these findings, it will be important to elucidate the mechanism responsible for the generation of soluble receptor proteins.
In the future, it will be interesting to study the status of the slL-6R during inflammatory and infectious conditions. This might change our view of the function oflL-6 in various pathophysiological states. Moreover, the IL-6/IL-6R complex, and not IL-6 alone, might be regarded as the active cytokine in vivo. To further address this question, it will be interesting to generate double transgenic mice, expressing hlL-6 in conjunction with the shlL-6R.
